Establishing immune scoring model based on combination of the number, function, and phenotype of lymphocytes

Tang, Guoqing; Xu, Yuan; Luo, Ying; Lin, Qun; Chen, Zhishui; Xing, Xue; Song, Huijuan; Wu, Shiji; Hou, Hongyan; Yu, Jing; L, Mao; Liu, Weiyong; Sun, Ziyong

doi:10.18632/aging.103208

Cited by 20 publications

(23 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2C – 2D ). The possible reasons of the stromal and immune score difference between >65 group and age ≤ 65 group could be as follows: Firstly, the correlation between immunity and age is a little controversial, with different results in different studies( Hirokawa et al, 2013 ; Tang et al, 2020 ; Weiss et al, 2016 ). Moreover, the original purpose of TCGA project is to design for molecular study.…”

Section: Discussionmentioning

confidence: 99%

“…For example, high ARL4C expression is an essential prognostic factor in LUAD (Kimura et al, 2020). However, a single gene biomarker is insufficient to produce comprehensive predictive effects and immune prognostic models were proposed for LUADs recently (Luo et al, 2020;Yang et al, 2019;Yue, Ma & Zhou, 2019). Until now, only few biomarkers for LUADs have been developed and there is a need to identify more pathways for new biomarkers including sensitive biomarkers which can provide individual therapeutic strategies for patients.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Identification of an immune prognostic 11-gene signature for lung adenocarcinoma

Yang

Hao

Cui

et al. 2021

PeerJ

View full text Add to dashboard Cite

Background The immunological tumour microenvironment (TME) has occupied a very important position in the beginning and progression of non-small cell lung cancer (NSCLC). Prognosis of lung adenocarcinoma (LUAD) remains poor for the local progression and widely metastases at the time of clinical diagnosis. Our objective is to identify a potential signature model to improve prognosis of LUAD. Methods With the aim to identify a novel immune prognostic signature associated with overall survival (OS), we analysed LUADs extracted from The Cancer Genome Atlas (TCGA). Immune scores and stromal scores of TCGA-LUAD were downloaded from Estimation of STromal and Immune cells in MAlignant Tumour tissues Expression using data (ESTIMATE). LASSO COX regression was applied to build the prediction model. Then, the prognostic gene signature was validated in the GSE68465 dataset. Results The data from TCGA datasets showed patients in stage I and stage II had higher stromal scores than patients in stage IV (P < 0.05), and for immune score patients in stage I were higher than patients in stage III and stage IV (P < 0.05). The improved overall survivals were observed in high stromal score and immune score groups. Patients in the high-risk group exhibited the inferior OS (P = 2.501e − 05). By validating the 397 LUAD patients from GSE68465, we observed a better OS in the low-risk group compared to the high-risk group, which is consistent with the results from the TCGA cohort. Nomogram results showed that practical and predicted survival coincided very well, especially for 3-year survival. Conclusion We obtained an 11 immune score related gene signature model as an independent element to effectively classify LUADs into different risk groups, which might provide a support for precision treatments. Moreover, immune score may play a potential valuable sole for estimating OS in LUADs.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Identification of an immune prognostic 11-gene signature for lung adenocarcinoma

Yang

Hao

Cui

et al. 2021

PeerJ

View full text Add to dashboard Cite

show abstract

“…The evaluation of lymphocyte function should be conducted before chemotherapy at each time point. PMA/ionomycin-stimulated lymphocyte function assay was performed as described in our previous studies [ 16 , 17 ]. The procedures were described as follows: 1) 100 µl of whole blood was diluted with 400 µl of IMDM medium; 2) the diluted whole blood was stimulated with Leukocyte Activation Cocktail (Becton Dickinson GolgiPlug) for 4 h; 3) the cells were stained with the following monoclonal antibodies anti-CD45-PerCP (652,803), anti-CD3-TITC (349,201), anti-CD4-APC/H7 (341,115), anti-CD56-PE/Cy7 (652,825), and anti-CD8-PE (340,046), followed by fixation and permeabilized (554,722), and staining with intracellular anti-IFN-γ-APC antibody (554,702).…”

Section: Methodsmentioning

confidence: 99%

Dynamic changes in peripheral blood lymphocyte subset counts and functions in patients with diffuse large B cell lymphoma during chemotherapy

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background This study aimed to analyze the lymphocyte subsets, their activities and their dynamic changes during immunochemotherapy in patients newly diagnosed with diffuse large B cell lymphoma (DLBCL). Methods Patients with DLBCL (n = 33) were included in the present study. Their peripheral lymphocyte subsets, phenotypes and functions were detected using flow cytometry. The dynamic results of lymphocyte activities were available for 18 patients. Results Compared with healthy controls (HCs), the counts of CD3+, CD4+, and CD8+ T cells as well as those NK cells decreased in patients newly diagnosed with DLBCL, mainly attributed to patients with high risk of prognosis assessed by International Prognostic Index (IPI) score. Lymphocyte counts didn’t present significant difference between high risk (IPI scores 3–5) and low risk patients (IPI scores 0–2), but CD4+ T cells and CD8+ T cells expressed higher levels of CD28 and HLA-DR, respectively, in patients with IPI score ranging from 3 to 5. Patients at high risk harbored higher percentage of regulatory T cells (Tregs), and their CD4+ and CD8+ T cells produced lower levels of IFN-γ, reflecting an impaired cellular immune response. The dynamic changes of lymphocyte numbers and functions during treatment were further investigated. Total counts of CD3+, CD4+, CD8+ T and NK cells progressively decreased because of the cytotoxicity of chemotherapy and then gradually recovered after six cycles treatment (rituximab combined with cyclophosphamide, doxorubicin, vincristine and prednisone, R-CHOP). The functions of CD4+ and CD8+ T cells recovered by the end of two cycles R-CHOP treatment, although NK cell function was not significantly affected throughout treatment. These results suggest that the counts and functions of lymphocytes are significantly decreased in patients with DLBCL, particularly those of CD4+ and CD8+ T cells. Conclusions The absolute counts and functions of CD4+, CD8+ T cells, which were significantly lower in patients with DLBCL, gradually recovered after effective treatment. Therefore, combined detection of T cell counts and functions are critically important for administering effective personalized immunotherapy as well as for identifying new prognostic markers or DLBCL.

show abstract

“…In addition, several studies have identified the specific characteristics of the immunophenotype in TB patients ( 28 , 29 ). Furthermore, our team has previously introduced a novel method-lymphocyte function assay for evaluating lymphocyte function ( 30 , 31 ). The test could reflect the activation, chemotaxis, and cytotoxicity of lymphocytes through the percentage of IFN-γ released under PMA/ionomycin stimulation ( 32 ).…”

Section: Introductionmentioning

confidence: 99%

Lymphocyte-Related Immunological Indicators for Stratifying Mycobacterium tuberculosis Infection

et al. 2021

Self Cite

View full text Add to dashboard Cite

BackgroundEasily accessible tools that reliably stratify Mycobacterium tuberculosis (MTB) infection are needed to facilitate the improvement of clinical management. The current study attempts to reveal lymphocyte-related immune characteristics of active tuberculosis (ATB) patients and establish immunodiagnostic model for discriminating ATB from latent tuberculosis infection (LTBI) and healthy controls (HC).MethodsA total of 171 subjects consisted of 54 ATB, 57 LTBI, and 60 HC were consecutively recruited at Tongji hospital from January 2019 to January 2021. All participants were tested for lymphocyte subsets, phenotype, and function. Other examination including T-SPOT and microbiological detection for MTB were performed simultaneously.ResultsCompared with LTBI and HC, ATB patients exhibited significantly lower number and function of lymphocytes including CD4+ T cells, CD8+ T cells and NK cells, and significantly higher T cell activation represented by HLA-DR and proportion of immunosuppressive cells represented by Treg. An immunodiagnostic model based on the combination of NK cell number, HLA-DR+CD3+ T cells, Treg, CD4+ T cell function, and NK cell function was built using logistic regression. Based on receiver operating characteristic curve analysis, the area under the curve (AUC) of the diagnostic model was 0.920 (95% CI, 0.867-0.973) in distinguishing ATB from LTBI, while the cut-off value of 0.676 produced a sensitivity of 81.48% (95% CI, 69.16%-89.62%) and specificity of 91.23% (95% CI, 81.06%-96.20%). Meanwhile, AUC analysis between ATB and HC according to the diagnostic model was 0.911 (95% CI, 0.855-0.967), with a sensitivity of 81.48% (95% CI, 69.16%-89.62%) and a specificity of 90.00% (95% CI, 79.85%-95.34%).ConclusionsOur study demonstrated that the immunodiagnostic model established by the combination of lymphocyte-related indicators could facilitate the status differentiation of MTB infection.

show abstract

Establishing immune scoring model based on combination of the number, function, and phenotype of lymphocytes

Cited by 20 publications

References 41 publications

Identification of an immune prognostic 11-gene signature for lung adenocarcinoma

Identification of an immune prognostic 11-gene signature for lung adenocarcinoma

Dynamic changes in peripheral blood lymphocyte subset counts and functions in patients with diffuse large B cell lymphoma during chemotherapy

Lymphocyte-Related Immunological Indicators for Stratifying Mycobacterium tuberculosis Infection

Contact Info

Product

Resources

About